Dear Colleagues,

Cancers have long been a big and difficult challenge in healthcare of human due to the high lethalities and lack of effective treatments. Thanks to the collaborative effectors of scientists from different disciplines, e.g., cancer biologists, molecular geneticists, bioinformaticians, statisticians, pharmacologists, and clinicians, targeted therapies have been developed for specific types of cancers in recent years.

Targeted therapies vented a new era for cancer medication and healthcare. Through targeting specific genetic mutations harbored by cancer patients, parts of active oncogenes and their products may be inactivated. Hence the progression of cancers could be hindered or slowed down. In such way, parts of cancer patients whose tumorgenesis is driven by those specific mutations of specific oncogenes, could live for longer time when target therapies are appropriately used for treatments. For example, given to drugs’ good treatment efficacy, the United States Food and Drug Administration has proved the sotorasib and adagrasib for treating non-small lung cancer patients who are carrying the KRAS G12C mutation.

Nevertheless, similar to other targeted therapies, aforementioned drugs of targeted therapy only work well on a limited part of cancer patients. Therefore, the rest parts of cancer patients and healthcare institutions are urgently calling for novel and effective targeted therapies which is able to cover and save more patients.

To this end, collaborative efforts of scientists from different disciplines are required. For instance, cancer biologists and geneticists could carry out genotypic and phenotypic studies, which could shed lights on how genetic mutations affect the disease phenotypes and physiological statuses. Bioinformaticians and pharmacologists could work together to examine whether specific drugs work well against specific genotypes and phenotypes. And clinicians and biostatisticians would be able to observe, analyze, identify, evaluate and finally report the treatment effects and outcomes in clinical cancer research projects or trials.  

Thus, we are calling research community for sharing your insightful and state-of-art research advancements with us. Studies relevant to Molecular Oncology and Oncotherapy, Cancer Biology and Genetics, Oncogene Mutation Effects, Precision Medication and Targeted Therapies of Cancer, Cancer Genomics/Proteomics and Phenomics, Cancer Genotype/Phenotype Studies, Cancer Pharmacology and Pharmacometrics, Cancer Pharmacogenetics and Pharmacogenomics, etc. are welcome.

 

We look forward to receiving your contributions of review and research article.

Hui-Heng LIN (Jeremy), Ph.D., M.Sc.Med.

Section Editor

Trends in Genetics and Evolution

ORCID: 0000-0003-4060-7336 (orcid.org)

E-mail: molgen.v@gmail.com

Oncology; Oncotherapy; Oncogene Mutations; Targeted therapy; Cancer Genetics; Cancer Genomics; Cancer Pharmacology; Cancer pharmacogenetics, Cancer Pharmacogenomics; Cancer Proteomics;